| 000 | 01776 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514001618.0 | ||
| 264 | 0 | _c20010607 | |
| 008 | 200106s 0 0 eng d | ||
| 022 | _a0028-4793 | ||
| 024 | 7 |
_a10.1056/NEJM200105313442201 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPacker, M | |
| 245 | 0 | 0 |
_aEffect of carvedilol on survival in severe chronic heart failure. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cMay 2001 |
||
| 300 |
_a1651-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xadverse effects |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarbazoles _xadverse effects |
| 650 | 0 | 4 | _aCarvedilol |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Failure _xdrug therapy |
| 650 | 0 | 4 |
_aHospitalization _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPropanolamines _xadverse effects |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aCoats, A J | |
| 700 | 1 | _aFowler, M B | |
| 700 | 1 | _aKatus, H A | |
| 700 | 1 | _aKrum, H | |
| 700 | 1 | _aMohacsi, P | |
| 700 | 1 | _aRouleau, J L | |
| 700 | 1 | _aTendera, M | |
| 700 | 1 | _aCastaigne, A | |
| 700 | 1 | _aRoecker, E B | |
| 700 | 1 | _aSchultz, M K | |
| 700 | 1 | _aDeMets, D L | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 344 _gno. 22 _gp. 1651-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJM200105313442201 _zAvailable from publisher's website |
| 999 |
_c11317238 _d11317238 |
||